The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Update May 15, 2015 09:10AM
UPDATE: Can-Fite BioPharma's (CANF) CF101 Phase 2/3 Missed Primary Endpoint; Roth Downgrades to Neutral Mar 30, 2015 12:22PM
Can-Fite Bio Pharma's (CANF) CF101 Receives Additional Validation with Latest Agreement - Roth Mar 23, 2015 11:39AM
Can-Fite BioPharma (CANF) Reaches Important Milestone; Psoriasis Data Expected Soon - Roth Mar 18, 2015 10:46AM
Roth Positive on Can-Fite Bio Pharma (CANF) Following Completion of CF101 Phase 2/3 Feb 4, 2015 09:17AM


Dec 29, 2014 08:22AM Roth Capital Lowers PT on Can-Fite BioPharma (CANF) to $20; CF101 Remains Key Catalyst
Dec 1, 2014 09:54AM Roth Affirms Can-Fite BioPharma (CANF) at 'Buy' Following Q3 Results; Still Sees FY15 as 'Breakout' Year
Nov 18, 2014 12:26PM Significant Partnership Could be in Store for Can-Fite (CANF) - Roth
Mar 10, 2014 12:53PM Can-Fite BioPharma (CANF) Closes 1.48M ADS, Warrants Private Placement
Dec 23, 2013 09:20AM Can-Fite BioPharma (CANF) Target Raised to $28 at Roth Capital